Compare Organon & Co. Common Stock (OGN) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Sony Group Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Sony Group Corp trades at $24.47 (market cap $140.46B). The key difference: Sony Group Corp is far larger — about 38.8× Organon & Co. Common Stock's market cap, and Sony Group Corp pays the higher dividend (0.65%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Sony Group Corp for 96 Days on average.
| OGN | SONY | |
|---|---|---|
Market Cap | $3.62B | $140.46B |
Volume | 2,892,999 | 5,764,125 |
Sector | Health | Technology |
52-Week High | $13.81 | $30.26 |
52-Week Low | $5.70 | $19.32 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $11.04B | $138.37B |
Dividend Yield | 0.58% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Sony trades at $24.36, up 0.41% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats, though Q1 2026 missed expectations. Revenue remains stable around $12.96T with improving operating cash flow of $2.32T. Analyst sentiment is strongly positive with 11 buy ratings and no sell recommendations, while recent news highlights Sony's content moat and AI litigation developments.
Sony presents a compelling investment case with solid fundamentals and strong analyst support, though negative net income margin and ROE raise concerns. The stock's valuation appears reasonable with P/E of 20.65 and EV/EBITDA of 8.05. Key risks include content competition and AI-related legal challenges, while opportunities lie in Sony's entertainment ecosystem and strategic expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
